LCB10 0200

Drug Profile

LCB10 0200

Alternative Names: GT-1; LCB10-0200

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LegoChem Biosciences
  • Developer Geom Therapeutics; LegoChem Biosciences
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 13 Sep 2017 Geom Therapeutics plans a phase I trial in Healthy volunteers in USA, in 2018
  • 13 Sep 2017 Geom Therapeutics intends to submit an IND to the US FDA for Gram-negative infections in 2H 2017
  • 13 Sep 2017 Geom Therapeutics enters into Clinical Trial agreement with the National Institute of Allergy and Infectious Diseases for phase I trial of LCB10 0200
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top